FDA Approves Ilumya for Psoriatic Arthritis Treatment as Only Office-Administered IL-23 Inhibitor

0 points · first seen 5h ago · 1 outlet · 0 comments

Psoriatic arthritis treatment now includes Ilumya (tildrakizumab-asmn) after FDA approval on October 30, 2026. Sun Pharma IL-23 inhibitor is only biologic in its class requiring in-office administration for every dose, setting it apart from self-injectable rivals guselkumab and risankizumab approved for the same indication. — Tech Times

save

· share to X · Bluesky · copy link